Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Fig. 4

Efficacy of PI3K inhibitors in vemurafenib resistant cell lines. a Six melanoma lines, originally sensitive to vemurafenib, were treated with increasing concentrations of vemurafenib over a period of 2 months to make the drug resistant clones. These clones were then tested for their sensitivity for (b) Vemurafenib, (c) CI1040 and (d) ZSTK474. Cell viability was determined using the sulforhodamine B (SRB) assay. Data were from 3 to 4 independent experiments performed in duplicates

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us